NIKKEI 225
39,095.67 +478.57 (+1.24%) HANG SENG
18,930.02 -265.58 (-1.38%) CRUDE OIL
77.08 -0.49 (-0.63%) GOLD FUTURES
2,374.40 -18.50 (-0.77%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,520.33 -350.66 (-0.64%)
Eliem Therapeutics, Inc. (ELYM)
After hours:
| Previous close | 7.84 |
| Open | 7.88 |
| Bid | 7.80 x 400 |
| Ask | 7.93 x 400 |
| Day's range | 7.60 - 8.18 |
| 52-week range | 2.34 - 11.55 |
| Volume | |
| Avg. volume | 887,282 |
| Market cap | 228.948M |
| Beta (5Y monthly) | -0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.30 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BenzingaEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Eliem Therapeutics Inc (NASDAQ:ELYM) has agreed to acquire Tenet Medicines Inc., a development-stage private biotechnology company. The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In June 2023, Eliem Therapeutics completed a review of its business, including the status of its programs, resources, and capabilities. The compa
GlobeNewswireEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Co
Simply Wall St.Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
